Stay updated on Elranatamab Combo in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Elranatamab Combo in Myeloma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Recruitment locations were expanded, adding numerous centers across various countries and updating the total number of locations from 39 to 89. The update includes detailed site information and current recruiting statuses to reflect broader access for potential participants.
    Difference
    7%
    Check dated 2026-05-15T14:27:55.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Taoyuan, Taiwan (333) was added as a new site and the total number of locations is now listed as 39; several previously listed sites were removed or had their recruitment statuses updated across multiple countries.
    Difference
    5%
    Check dated 2026-05-08T12:11:14.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The related topics block loses the 'Multiple myeloma' entry and the 'MedlinePlus Genetics' link, reducing ancillary cross-references while keeping the main study details intact.
    Difference
    0.1%
    Check dated 2026-05-01T10:05:35.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The study record was updated with newer “first/last update” dates and the site revision version, and the recruitment status was changed from not yet recruiting to recruiting.
    Difference
    0.2%
    Check dated 2026-04-24T06:32:22.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    Added MagnetisMM-6 study details with an open-label, two-arm, multicenter randomized design comparing Elranatamab + Daratumumab + Lenalidomide vs Daratumab + Bortezomib + Lenalidomide + Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma, including Part 1 safety/dose characterization and Part 2 MRD-negative CR rate and PFS endpoints, and noted 89 locations. Deleted the earlier version that described the trial as transplant-ineligible or transplant-deferred participants with slightly different wording and site count (88 vs 89), reflecting updated eligibility scope and site count.
    Difference
    1%
    Check dated 2026-04-17T02:50:02.000Z thumbnail image
  8. Check
    54 days ago
    Change Detected
    Summary
    Removed the core disease term 'Multiple myeloma' and a related MedlinePlus Genetics topic, reducing essential context about the study's focus.
    Difference
    0.1%
    Check dated 2026-04-09T21:47:01.000Z thumbnail image

Stay in the know with updates to Elranatamab Combo in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Elranatamab Combo in Myeloma Clinical Trial page.